抗血管生成联合免疫检查点抑制剂治疗晚期肾癌的理论基础及研究进展

Theoretical basis and research progress of anti-angiogenesis combined with immune checkpoint inhibitors in the treatment of advanced renal carcinoma

近年来,抗血管生成联合免疫检查点抑制剂治疗恶性肿瘤已经成为研究热点。这些研究的理论基础是免疫系统与血管生成系统相互作用可以增加抗肿瘤活性。例如:美国食品和药物管理局(Food and Drug Administration,FAD)批准阿维单抗联合阿昔替尼用于晚期肾癌一线治疗。尽管抗血管生成联合免疫检查点抑制剂在晚期肾癌治疗方面取得了不错成果,但同时也加重了与治疗相关的不良反应。虽然大多数患者在免疫检查点抑制剂治疗间歇期出现了与免疫治疗相关的不良反应,但研究发现联合治疗并未加重与免疫治疗相关的不良反应,而是与抗血管生成药的毒性反应有关。因此,本文旨在总结抗血管生成联合免疫检查点抑制剂治疗晚期肾癌的理论基础与研究进展进行如下综述。

In recent years, anti-angiogenesis combined with immune checkpoint inhibitors in the treatment of malignant tumors has become a research hotspot.The theoretical basis of these studies is that the interaction between the immune system and the angiogenic system increases anti-tumor activity.For example, Food and Drug Administration(FDA) has approved avelumab in combination with axitinib for first-line treatment of advanced kidney cancer.Although anti-angiogenesis combined with immune checkpoint inhibitors has been shown to be effective in the treatment of advanced renal cancer, they have also exacerbated treatment-related adverse reactions.Although most patients experienced irAE during the interval of immune checkpoint inhibitors’ treatment, it was found that the combination therapy did not aggravate irAEs, but was associated with the toxic effects of antiangiogenic drugs.Therefore, the purpose of this article is to summarize the theoretical basis and research progress of advanced renal carcinoma with anti-angiogenesis combined with immune checkpoint inhibitors.